6 August 2023 in Chemical Engineering Journal
6 June 2021 in Cell Proliferation
Objectives: The treatment of ameloblastoma, an odontogenic epithelial tumour destroying jawbone, mainly depends on radical destructive resections. Other therapeutic options are limited by the characteristics of ameloblastoma, such as high recurrence rates and resistance to radiation and chemotherapy, which implies possible existence of cancer stem cells (CSCs) in ameloblastoma. Here, we identified a putative CSC population in immortalized and primary human ameloblastoma cells and examined possible therapeutic reagents to reduce the CSC population.Methods: We investigated subpopulations of AM‐1 cell line and human ameloblastoma cells using immunocytochemistry and flow cytometry and the effects of Wnt signalling activators on the 2‐ and 3‐dimensional cultured ameloblastoma cells using molecular biological analyses.Result: Among heterogenous ameloblastoma cells, small‐sized and round‐shaped cells were found to be proliferative and expressed a marker of dental epithelial stem cells, SRY‐box 2 (Sox2). Exogenous activation of Wnt signalling using glycogen synthase kinase 3β inhibitors, lithium chloride (LiCl) and valproic acid (VPA), increased the cell size and decreased proliferation of cells and expression of Sox2 in 2 dimensionally cultured AM‐1 and human primary ameloblastoma cells. Furthermore, the growth of 3 dimensionally cultured AM‐1 cells as suspended or embedded in gel was suppressed by treatment with Wnt signalling activators, VPA and CHIR99021, or antibodies to sclerostin, an antagonist of Wnt signalling.Conclusion: We suggest that Wnt signalling activators are potential drug candidates to suppress CSCs in ameloblastoma.
22 August 2023 in Journal of Advanced Research
Most mineralized tissues in our body are present in bones and teeth. Human induced pluripotent stem cells (hiPSCs) are promising candidates for cell therapy to help regenerate bone defects and teeth loss. The extracellular matrix (ECM) is a non-cellular structure secreted by cells. Studies on the dynamic microenvironment of ECM are necessary for stem cell-based therapies. We aim to optimize an effective protocol for hiPSC differentiation into dental cells without utilizing animal-derived factors or cell feeders that can be applied to humans and to mineralize differentiated dental cells into hard tissues. For the differentiation of both dental epithelial cells (DECs) and dental mesenchymal cells (DMCs) from hiPSCs, an embryoid body (EB) was formed from hiPSCs. hiPSC were differentiated into neural crest cells with an induction medium utilized in our previous study, and hiPSC-derived DECs were differentiated with a BMP-modulated customized medium. hiPSC-dental cells were then characterized, analyzed, and validated with transcriptomic analysis, western blotting, and RT-qPCR. To form mineralized tissues, hiPSC-derived DECs were recombined with hiPSC-derived DMCs encapsulated in various biomaterials, including gelatin methacryloyl (GelMA), collagen, and agar matrix. These hiPSC-derived dental cells are highly osteogenic and chondro-osteogenic in photocrosslinkable GelMA hydrogel and collagen type I microenvironments. Furthermore, hiPSC-derived dental cells in agar gel matrix induced the formation of a bioengineered tooth. Our study provides an approach for applying hiPSCs for hard tissue regeneration, including tooth and bone. This study has immense potential to provide a novel technology for bioengineering organs for various regenerative therapies.
6 July 2022 in Cell Proliferation
Objectives: Ameloblastoma (AM) has been known as a benign but locally invasive tumour with high recurrence rates. Invasive behaviour of the AM results in destruction of the adjacent jawbone and the non‐detectable remnants during surgery, interrupting the complete elimination of cancer cells.Methods: To explore novel targets for the tumour cell invasion, a transcriptomic analysis between AM and odontogenic keratocyst were performed through next‐generation sequencing in detail.Results: Enrichment of CACNA1C gene (encoding Cav1.2) in AM, a subunit of the L‐type voltage‐gated calcium channel (VGCC) was observed for the first time. The expression and channel activity of Cav1.2 was confirmed by immunostaining and calcium imaging in the patient samples or primary cells. Verapamil, L‐type VGCC blocker revealed suppression of the Ca2+‐induced cell aggregation and collective invasion of AM cells in vitro. Furthermore, the effect of verapamil in suppressing AM invasion into the adjacent bone was confirmed through orthotopic xenograft model specifically.Conclusion: Taken together, Cav1.2 maybe considered to be a therapeutic candidate to decrease the collective migration and invasion of AM.
3 December 2025 in Journal of Advanced Research
Ameloblastoma (AM) frequently develops resistance to the BRAF inhibitor vemurafenib, primarily mediated by ameloblastoma-associated fibroblasts (AMFs). However, the potential contribution of the circadian clock in this resistance has not been explored. This study aimed to elucidate the role of the BMAL1-LHX8 axis during tumor-stroma crosstalk, and to investigate the therapeutic potential of targeting this axis to augment vemurafenib sensitivity for AM. Patient-derived AM cells and AMFs were utilized to reconstruct the stroma-rich AM tumoroid in-vitro for recapitulating the tumor-stroma interplay and assessing the pharmacological effect of vemurafenib. Time-series RNA-sequencing, luciferase assays, and CRISPR/Cas9 gene editing were used to define the transcriptional landscape and the BMAL1-LHX8 regulatory network. The efficacy of combining the clock modulator GSK4112 with vemurafenib was assessed in stroma-rich AM tumoroids and cell line-based xenograft models. Patient-derived AMFs exhibit enhanced secretory activity, and elevated metabolic and contractile functions contribute to increased stromal stiffness through ECM remodeling in AM. Tumor-stroma crosstalk was recapitulated in stroma-rich AM tumoroid, which is evidenced by the dynamic alteration of normal fibroblasts (NFs) to AMF-like state. Transcriptomic profiling of stroma-rich tumoroids revealed severe disruption of the molecular clock and LHX8 in AMFs. Functional studies demonstrated that BMAL1-driven LHX8 expression promotes pro-tumorigenic AMF activities, including growth factor secretion and ECM remodeling. Critically, pharmacological inhibition of the BMAL1-LHX8 axis with GSK4112 potently sensitized AM to vemurafenib in both stroma-rich tumoroid and xenograft models. Our findings reveal the role of the BMAL1-LHX8 axis in underlying AMF-mediated drug resistance in AM, and propose that the molecular clock modulation in tumor-stroma crosstalk represents a potential therapeutic avenue for ameloblastoma.
1 May 2019 in Medical Hypotheses